PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,

Similar documents
Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR

Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR

Welcome Address. Symposium Chairmen. Dear friends and colleagues,

Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK

10 th International Congress on Peritoneal Surface Malignancies

FINAL SCIENTIFIC PROGRAMME

CURRICULUM VITAE 2005

Results of a French Multicentric Analysis

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei

Department of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2

Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer

How to deal with patients with isolated peritoneal metastases

Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS)

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)

POLICIES AND PROCEDURE MANUAL

Gastric cancer treated with pressurized intraperitoneal aerosol chemotherapy: revising an option for peritoneal carcinomatosis

International scientific-practical conference «Management of Peritoneal Surfaces Malignancy» Irkutsk, August 9-11, Program

Rationale for the treatment. Peritoneal Surface Malignancy

U T C H. No disclosure

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database

CRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis

MP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Computerized System for Staging Peritoneal Surface Malignancies

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Pre-operative assessment of patients for cytoreduction and HIPEC

Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview

Heated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

HIPEC AND COMPLICATED COLORECTAL SURGERY

Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol

Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria

Treatment of peritoneal metastases from colorectal cancer

All along the colon: multimodality imaging and staging

ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2018) 25:

ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain

1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011

This is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.

TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS

Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin

Surgical Oncology, Mercy Medical Center, Baltimore, MD

Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Correspondence should be addressed to David Morris; Received 17 February 2013; Revised 14 April 2013; Accepted 24 June 2013

IJC International Journal of Cancer

Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Colorectal peritoneal metastases and IMPACT

International Journal of Hyperthermia. ISSN: (Print) (Online) Journal homepage:

Made available by Hasselt University Library in Document

COURSES ENDORSEMENT AND ACCREDITATION

Optimal drugs for HIPEC in different tumors

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis

Corporate Medical Policy

Appendix adenocarcinomas are rare and heterogeneous

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer

6 th MD ANDERSON INTERNATIONAL MEETING IN EMBRACING NEW STANDARDS OF CARE IN GYNECOLOGIC CANCERS PRELIMINARY PROGRAM. Meeting Directors:

Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies

Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry

Version 1.11 of 20/07/2018

CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal

Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES

MP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None

( Dedrick et al 1978 ) ( Armstrong et al 2006 )

Surgical Department, Didimotichon General Hospital, Didimotichon, Greece 2

Current Techniques in the Treatment of Severe Endometriosis

30 th European Heart Diseases and Heart Failure Congress

Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.

Care, 4 University of North Dakota, 5 Christiana Care Health System, 6 UMass Memorial Medical Center,

COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini

Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

5 th International Video Workshop

Kathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.

Clinicopathological features and prognosis of pseudomyxoma peritonei

Short-term Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Preliminary Analysis of a Multicentre Study

Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?

Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS

Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review past, present and future

Gastrointestinal Oncology

Abstract EDITORIAL Madrid, Spain. Telephone:

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital

Purpose. Page 2 of 24

Information for health professionals - pseudomyxoma peritonei

TGH Annual Report (2016) Editorial Office

Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations

Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer

Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer

Peritoneal carcinomatosis cytoreductive surgery and. HIPEC - overview and basics

Allied Health: Sustainable Integrated Health Care for all Australians

VENUE. NMI Natural and Medical Sciences Institute at the University of Tübingen. Markwiesenstrasse 55, Reutlingen, Germany

News Letter. Thanks letter AOCC2014. Asian Organization for Crohn s and Colitis. Vol.1 - Issue 1. Dear Colleagues, Dear Participants,

Transcription:

11 th International Workshop on Peritoneal Surface Malignancy PRELIMINARY PROGRAM SEPTEMBER 9-11, 2018 Maison de la Chimie, Paris, France www.psogi2018.com

9THSATURDAY 8TH 2SUNDAY Saturday, September 8 th 16h00-18h00 Registration Sunday, September 9 th 07h30 Registration 08h15 Welcome Remarks PH. Sugarbaker (USA) - O. Glehen (France) - D. Goéré (France) - M. Pocard (France) 08h30-12h15 Radiological consensus session Organizing: A. Dohan (France) - P. Rousset (France) 08h30 Colorectal and gastric free papers Chairmen: O. Glehen (France) - PH. Sugarbaker (USA) 09h20 In practice Chairmen: R. Lo Dico (France) - Y. Yonemura (Japan) 1. Intraperitoneal chemotherapy: indications in gastric peritoneal metastases Speaker: J. Kitayama (Japan) 2. PIPAC: How I do it? Speaker: M. Hübner (Switzerland) 09h50 Take home message Evaluation of histological response to preoperative chemotherapy Chairmen: F. Bibeau (France) - P. Sammartino (Italy) Speaker: W. Solass (Germany) 10h00 BREAK - VISIT POSTERS AND EXHIBITS 10h30 Free papers session - Best communications Chairman: L. Gladieff (France) 11h00 Recent results of the randomized clinical trials and futures for colorectal and gastric peritoneal metastases Chairmen: D. Goéré (France) - S. Gonzales Moreno (Spain) - V. Verwaal (Denmark) PRODIGE 7 - F. Quenet (France) PROPHYLOCHIP - D. Goéré (France) COLOPEC - PJ. Tanis (The Netherlands) COMBATAC - P. Piso (Germany) GASTRIPEC- B. Rau (Germany) GASTRTICHIP - O. Glehen (France) 12h15 LUNCH - VISIT POSTERS AND EXHIBITS

13h30 Satellite Symposium: Debates: Procedures for HIPEC: open/closed/laparoscopy Chairmen: J. Esquivel (USA) - M. Pocard (France) 1. Pro open: Speaker: D. Bartlett (USA) 2. Pro closed: Speaker: O. Glehen (France) sponsored by 14h30 Translational research and pre-clinical models for peritoneal disease Chairmen: I. De Hingh (The Netherlands) - M. Pocard (France) 1. Animal model for PIPAC Speaker: W. Ceelen (Belgium) 2. PMP4Cure an European network Speaker: K. Flatmark (Norway) 3. Prophylaxis of peritoneal tumoral implants Speaker: M. Pocard (France) 4. Free papers SUNDAY 9 TH 14h30 Selected videos Chairmen: A. Nissan (Israël) - C. Arvieux (France) 15h10 Take home message: Screening before HIPEC Chairmen: H. Cashin (Sweden) - P. Rousset (France) Speaker: C. Dromain (France) 15h30 Satellite Symposium 16h00 BREAK - VISIT POSTERS AND EXHIBITS 16h30 Pathology of peritoneal disease Organizing: F. Bibeau (France) - P. Dartigues (France) 16h30 Radiology and Translational Research - Free papers Chairmen: A. Dohan (France) - W. Ceelen (Belgium) 17h20 Keynote Lecture: BIG DATA - applications for clinical research Chairman: V. Verwaal (Denmark) Speaker: JM. Bereder (France) 17h45 Clinical cases from the less to the more experienced surgeons Chairmen: O. Sgarbura (France) - A. Bhatt (India) 3

Monday, September 10 th 07h00 Registration 07h30 Meet the professor 4MONDAY 10TH 1. CT assessment versus laparoscopic assessment of peritoneal metastases prior to CRS O. Glehen (France) - P. Rousset (France) - K. Van der Speeten (Belgium) 2. Laparoscopic HIPEC: indications? M. Alyami (France) - J. Esquivel (USA) - B. Rau (Germany) 3. Management of parietal defect R. Lo Dico (France) - D. Morris (Australia) - G. Passot (France) 4. Management of intraoperative hyperthermia V. Billard (France) - I. de Hingh (The Netherlands) - M. Pocard (France) 5. Pathology and peritoneal malignancies F. Bibeau (France) - N. Carr (USA) - W. Solass (USA) 08h30 Peritoneal primary malignancies - Free papers Chairmen: EA. Levine (USA) - B. Moran (UK) 09h20 In practice Chairmen: J. Esquivel (USA) - D. Morris (USA) 1. New classification for peritoneal pseudomyxoma Speaker: P. Dartigues (France) 2. LAMN, surveillance or HIPEC? Speaker: J. Baumgartner (USA) 09h50 Take home message and vote Towards a consensus for treatment of non resectable malignant peritoneal mesothelioma Chairmen: M. Deraco (Italy) - G. Freyer (France) Speaker: M. Ducreux (France) 10h15 BREAK - VISIT POSTERS AND EXHIBITS 10h45 Consensus statement for Peritoneal Mesothelioma and Pseudomyxoma peritonei 11h15 Recent results of the randomized clinical trials and futures for primary malignancies Chairmen: D. Baratti (Italy) - B. Moran (UK) - F. Quenet (France) 12h15 LUNCH - VISIT POSTERS AND EXHIBITS 201 232 233 234 269

13h30 Satellite Symposium 14h30 Anesthesiology and intensive care for HIPEC Chairmen: E. Gayat (France) - V. Billard (France) 14h30 Selected videos Chairmen: C. Eveno (France) - J. Ferreira Loureiro (Brazil) 5MONDAY 10TH 15h10 Debates about pre - and / or post systemic chemotherapy associated to HIPEC for colorectal peritoneal metastases Chairmen: B. Rau (Germany) - Y. Li (China) 1. Pro systemic chemotherapy Speaker: C. Eveno (France) 2. Contra systemic chemotherapy Speaker: I. De Hingh (The Netherlands) 15h40 Take home message: Management of per and postoperative intraperitoneal bleeding Chairmen: C. Brigand (France) - P. Piso (Germany) Speaker: PH. Sugarbaker (USA) 16h00 BREAK - VISIT POSTERS AND EXHIBITS 16h30 Intraperitoneal Drugs and Pharmacology Chairmen: N. Bakrin (France) - K. Van der Speeten (The Netherlands) 16h30 Anesthesia Early recovery Preoperative preparation Nutrition Free papers Chairmen: G. Passot (France) F. Mohamed (UK) 17h10 Satellite Symposium: Debates: Hyperthermia: yes or not? Chairmen: I. de Hingh (The Netherlands) - F. Quenet (France) 1. Pro hyperthermia: Speaker: D. Morris (Australia) 2. Contra hyperthermia: Speaker: W. Ceelen (Belgium) 17h45 Clinical cases from the less to the more experienced surgeons Chairmen: JB. Delhorme (France) - M. Gelli (France) 20h00 CONGRESS BANQUET

NURSING AND ALLIED HEALTH SESSIONS DAY 08h30 201 08h45 Invited conference Cytoreductive surgery and HIPEC: current indications and issues 09h15 Free session 1: Modalities of IP chemotherapy and the related current issues 10h15 BREAK - VISIT POSTERS AND EXHIBITS 10h45 Round table 1: The nurse in the OR: education practices all around the globe 6MONDAY 10TH 11h30 Free session 2: Allied professionals roles and peritoneal carcinomatosis treatment 12h15 LUNCH - VISIT POSTERS AND EXHIBITS 13h30 Invited conference Checklist and prevention of accidents in the operative room 14h15 Free session 3: The management of HIPEC patients in the OR 15h00 Round table 2: Caregivers and working environment safety: practices around the globe 16h00 BREAK - VISIT POSTERS AND EXHIBITS 16h30 Free session 4: PIPAC new challenges in the OR and in the surgery department 17h30 CLOSING REMARKS: THE ORGANIZING COMMITTEE ORGANIZERS OF BEIJING 2020

Tuesday, September 11 th 07h00 Registration 07h30 Meet the professor 7TUESDAY 11TH 1. How to set up a national HIPEC program (Instances and registries) A. Bhatt (India) - F. Dumont (France) - C. Quadros (Brazil) 2. How to set up a national PIPAC program N. Bakrin (France) - M. Hübner (Switerland) - C. Tempfer (Germany) 3. New technology to detect non visible peritoneal deposits (indocyanine green ) J. Esquivel (USA) - M. Gelli (France) - G. Liberale (Belgium) 4. Requirement for stoma after complete pelvic peritonectomy with rectosigmoid colon resection and HIPEC C. Arvieux (France) - O. Glehen (France) - PH. Sugarbaker (USA) 5. Enhanced recovery and HIPEC D. Goéré (France) - F. Mohamed (UK) - G. Passot (France) 08h30 Peritoneal carcinomatosis from ovarian carcinoma free papers Chairmen: N. Bakrin (France) - A. Fagotti (Italy) 09h20 Controversial on the randomized clinical trials and futures for HIPEC in peritoneal carcinomatosis from ovarian cancer Chairmen: JM. Classe (France) - G. Freyer (France) - J. Spiliotis (Greece) HIPEC as standard or optional in first line treatment Pro: WJ. Van Driel (The Netherlands) Contra: G. Freyer (France) HIPEC as standard or optional in platine sensitive recurrence Pro: J. Spiliotis (Greece) Contra: A. Fagotti (Italy) HIPEC as standard or optional in platine resistant recurrence Pro: N. Bakrin (France) Contra: JM. Classe (France) 10h35 Award ceremony 10h45 BREAK - VISIT POSTERS AND EXHIBITS 11h15 Timing of surgery in peritoneal carcinomatosis from ovarian carcinoma Chairman: A. Fagotti (Italy) Speaker: DS. Chi (USA) 11h40 Free papers from clinical trials and futures for PIPAC Chairmen: M. Pocard (France) - M. Reymond (Germany) 12h45 Beijing PSOGI 2020 13h00 END OF THE MEETING 201 232 233 234 269